Developing methods to determine Akt/PKB in peripheral blood mononuclear cells of colorectal cancer patients

鉴于结直肠癌（CRC）患者的高死亡率，迫切需要一种方便， 更准确和具有成本效益的筛查测试，可以将患者分类为更密集的程序， 结肠镜检查这将改善患者的依从性和临床结果。CRC在女性中居第二位， 在加拿大和世界范围内，癌症是男性死亡的第三大原因，一直是重要的公共卫生问题。 问题. 2011年，加拿大估计有22，200例CRC病例，约9，000例死亡（加拿大人）。 癌症协会）。超过90%的局部结直肠癌患者存活超过5年。 不幸的是，很少有人接受筛查。疾病控制中心最近的一项调查报告说， 美国只有42%的高危人群接受过检测在真实的条件下，这意味着超过一半的 预计2013年将有56，290名美国人和10，000名加拿大人死于结直肠癌， 如果他们接受了筛查， 本Engage基金提案的目的是设计和开发一种基于流式细胞仪的细胞质Akt检测方法 这可能是早期发现或诊断CRC的标志物。 拟议研究的结果将有助于开发CRC的筛查技术， 除了减少与CRC相关的终身成本外，还为加拿大带来了经济效益。这份拨款申请 还将使PI和Emergent Biosolutions之间建立研究合作。

Given the high mortality rates in colorectal cancer (CRC) patients, there is an urgent need for a convenient, more accurate and cost-effective screening test that could triage patients for more intensive procedures such as colonoscopy. This would improve patient compliance and clinical outcomes. CRC is the second in females and third in males leading cause of cancer deaths in Canada and worldwide and has been a significant public health problem. In 2011, there were an estimated 22,200 cases of CRC in Canada, and some 9,000 died (Canadian Cancer Society). Over 90% of patients diagnosed with localized colorectal cancer survive more than five years. Unfortunately, very few people are screened. A recent survey by the Centers for Disease Control reported that only 42% of the at-risk population in America has been tested. In real terms this means that over half of the 56,290 Americans and the 10,000 Canadians expected to die of colorectal cancer in 2013 could have been saved if they had undergone screening. The objective of this Engage grant proposal is to design and develop a FACS based test for cytoplasmic Akt which could be a marker for early detection or diagnosis of CRC. The results of proposed research would aid in developing screening technology for CRC with potential for economic benefit to Canada in addition to reducing the lifetime costs associated with CRC. This grant proposal would also enable establishment of research collaboration between the PI and Emergent Biosolutions.